The FX PostThe FX Post
    What's Hot

    SEC Delays Decision on Truth Social’s Bitcoin ETF Amid Crypto Market Pause – TokenPost

    July 29, 2025

    401(k)s Now Pull Double Duty as Emergency Funds | PYMNTS.com

    July 28, 2025

    Cipher Mining ends board observer agreement with Bitfury Investors By Investing.com

    July 27, 2025
    The FX Post The FX Post
    • Best Fx Robots
    • Forex
      • News
      • Forex 101
      • Forex Forecasts
      • Broker Reviews
    • Crypto
      • News
      • Crypto 101
      • Crypto Forecasts
      • Crypto Reviews
    • Indices
      • News
      • Analysis
      • Commodities
      • Reviews
    • Automated Trading
      • Forex Signals
      • Forex Robots
      • Copy Trading
    • Top
      • Best Forex Robots
    The FX PostThe FX Post
    Home ยป VistaGen Therapeutics Phase 3 Study Results
    News

    VistaGen Therapeutics Phase 3 Study Results

    August 8, 20232 Mins Read
    Facebook Twitter Pinterest LinkedIn Reddit
    Share
    Facebook Twitter LinkedIn Pinterest Reddit

    Published by Dean Seal

    Shares of VistaGen Therapeutics have experienced a significant surge in early trading following the successful Phase 3 study of their fasedienol nasal spray as a treatment for social anxiety disorder. The study has achieved its primary endpoint, leading to a spike in the company’s stock.

    Impressive Market Performance

    After reaching a high of $24.71, marking a remarkable 14-fold increase from last Friday’s closing price of $1.68, the stock has currently settled at $13.50 in the early trading session. This substantial market response reflects the positive outcomes of VistaGen’s nasal spray study.

    Study Meets Primary and Secondary Endpoints

    The San Francisco-based biopharmaceutical company has announced that the Phase 3 study not only met its primary endpoint but also successfully achieved its secondary goals. Furthermore, the treatment was reported to be well-tolerated, exhibiting a favorable safety profile consistent with previous trials.

    Major Milestone in Social Anxiety Disorder Treatment

    VistaGen characterized this trial as a groundbreaking achievement, being the first positive study of an investigational therapy for social anxiety disorder in over 15 years. This success is a significant milestone that could potentially lead to improved treatment options for individuals living with this condition.

    Continued Development Despite Previous Setbacks

    Interestingly, this recent breakthrough comes just over a year after VistaGen’s PH94B nasal spray failed to achieve its primary endpoint in a Phase 3 study focused on adults with social anxiety disorder. Despite this setback, the company expressed its commitment to further developing the nasal spray, culminating in the current positive results.

    VistaGen shares previously hit an all-time low of $1.62 at the end of June, highlighting the considerable progress made since then.

    Markets are invaded by algorithms
    Secure your passive income with algo-based trading systems
    Learn more
    nasal spray Phase 3 study social anxiety disorder treatment VistaGen Therapeutics
    Share. Facebook Twitter Pinterest LinkedIn Reddit

    Related Posts

    SEC Delays Decision on Truth Social’s Bitcoin ETF Amid Crypto Market Pause – TokenPost

    July 29, 2025

    401(k)s Now Pull Double Duty as Emergency Funds | PYMNTS.com

    July 28, 2025

    Cipher Mining ends board observer agreement with Bitfury Investors By Investing.com

    July 27, 2025

    Tron Inc. Debuts on Nasdaq as Justin Sun Rings Opening Bell – TokenPost

    July 26, 2025
    Add A Comment

    Leave A Reply Cancel Reply

    8  +  1  =  

    Best FX Post
    Best Forex Robots (Expert Advisors) 2021

    Best Forex Robots (Expert Advisors) 2022: Passive Income From Algo Trading Systems

    July 7, 2021

    Top 10 Lending Platforms for Crypto Loans

    June 1, 2022
    forex eurusd trading charts

    Top 10 Best Forex Brokers In All Times

    June 1, 2022
    Recent Posts
    • SEC Delays Decision on Truth Social’s Bitcoin ETF Amid Crypto Market Pause – TokenPost
    • 401(k)s Now Pull Double Duty as Emergency Funds | PYMNTS.com
    • Cipher Mining ends board observer agreement with Bitfury Investors By Investing.com
    • Tron Inc. Debuts on Nasdaq as Justin Sun Rings Opening Bell – TokenPost
    • EFCC Takes Sensitization Campaign On Virtual Assets, Money Laundering To CBN – InfoStride News
    Featured Reviews

    Traders Connect Review

    May 18, 2023

    System Levels Review

    May 26, 2023
    TechBerry

    TechBerry Review: Pros, Cons, Recommendations

    September 18, 2021
    Categories
    • Analysis
    • Automated Trading
    • Best FX Post
    • Broker Reviews
    • Commodities
    • Copy Trading
    • Crypto
    • Crypto 101
    • Crypto Bots
    • Crypto Forecasts
    • Crypto Reviews
    • Crypto Robot
    • Forex
    • Forex 101
    • Forex Forecasts
    • Forex Robots
    • Forex Signals
    • Forex Signals
    • Guides
    • Indices
    • News
    • News
    • News
    • News
    • Reviews
    • Reviews
    • Uncategorized
    Twitter BlogLovin
    © 2025, Thefxpost.com.
    • Contact

    Type above and press Enter to search. Press Esc to cancel.